Publication Name	World Journal of Cardiology
Manuscript ID	18233
Country	Germany

Received	2015-04-13 08:40
Peer-Review Started	2015-04-18 17:22
To Make the First Decision	2015-05-13 19:44
Return for Revision	2015-05-19 14:01
Revised	2015-05-29 03:43
Second Decision	2015-07-24 11:38
Accepted by Journal Editor-in-Chief	2015-07-24 15:42
Accepted by Executive Editor-in-Chief	2015-08-03 15:52
Articles in Press	2015-08-03 15:52
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-09-09 20:56
Publish the Manuscript Online	2015-09-20 21:45

ISSN	1949-8462 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Cardiac & Cardiovascular Systems
Manuscript Type	Minireviews
Article Title	Challenging aspects of treatment strategies in heart failure with preserved ejection fraction: “Why did recent clinical trials fail?”
Manuscript Source	Invited Manuscript
All Author List	Peter Moritz Becher, Nina Fluschnik, Stefan Blankenberg and Dirk Westermann
Funding Agency and Grant Number
Corresponding Author	Peter Moritz Becher, MD, Department of General and Interventional Cardiology, University Heart Center Hamburg Eppendorf, Martinistraße 52, 20246 Hamburg, Germany. m.becher@uke.de
Key Words	Diastolic dysfunction; Preserved ejection fraction; Co-morbidities; Clinical trials
Core Tip	Heart failure (HF) has preserved left ventricular ejection fraction (HFpEF) accounts for approximately 50% of all patients diagnosed with HF, with similary poor outcomes. To date, only the prevention of HFpEF by treating the cardiovascular risk factors (coronary artery disease, atrial fibrillation, hypertension, diabetes, and obesity) has been shown to be efficient. This observation suggests that investigators in future trials should specify the indication of hospitalization for HF and may request to verify the details of patients’ admissions. We provide an outline and interpretation of recent clinical trials that failed to improve outcome and survival in patients with HF with preserved ejection fraction.
Publish Date	2015-09-20 21:45
Citation	Becher PM, Fluschnik N, Blankenberg S, Westermann D. Challenging aspects of treatment strategies in heart failure with preserved ejection fraction: “Why did recent clinical trials fail?” World J Cardiol 2015; 7(9): 544-554
URL	http://www.wjgnet.com/1949-8462/full/v7/i9/544.htm
DOI	http://dx.doi.org/10.4330/wjc.v7.i9.544

Full Article (PDF)	WJC-7-544.pdf
Full Article (Word)	WJC-7-544.doc
Manuscript File	18233-Review.doc
Answering Reviewers	18233-Answering reviewers.pdf
Audio Core Tip	18233-Audio core tip.wav
Conflict-of-Interest Disclosure Form	18233-Conflict-of-interest statement.pdf
Copyright License Agreement	18233-Copyright assignment.pdf
Peer-review Report	18233-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	18233-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	18233-Scientific misconduct check.pdf
Scientific Editor Work List	18233-Scientific editor work list.pdf